$NVCR
NovoCure Ltd Stock $nvcr

$nvcr Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-Q Financial Statement

#000164511321000112 Filed on October 28, 2021

Income Statement

Concept	2021 Q3	2020 Q3	2020 Q2
Revenue	$133.6M	$132.7M	$115.9M
YoY Change	0.71%	44.1%	33.69%
Cost Of Revenue	$30.21M	$28.40M	$25.47M
YoY Change	6.38%	24.0%	20.7%
Gross Profit	$103.4M	$104.3M	$90.45M
YoY Change	-0.83%	50.75%	37.87%
Gross Profit Margin	77.39%	78.6%	78.03%
Selling, General & Admin	$63.81M	$56.43M	$53.87M
YoY Change	13.09%	21.24%	19.81%
% of Gross Profit	61.71%	54.12%	59.55%
Research & Development	$48.14M	$32.82M	$29.92M
YoY Change	46.69%	74.88%	53.79%
% of Gross Profit	46.56%	31.48%	33.08%
Depreciation & Amortization	$2.734M	$2.190M	$2.600M
YoY Change	24.84%	13.47%	22.07%
% of Gross Profit	2.64%	2.1%	2.87%
Operating Expenses	$112.0M	$89.24M	$83.78M
YoY Change	25.45%	36.65%	30.08%
Operating Profit	-$8.552M	$15.02M	$6.668M
YoY Change	-156.93%	289.68%	457.53%
Interest Expense	-$1.981M	-$4.000M	-$2.600M
YoY Change	-50.48%	53.85%	116.67%
% of Operating Profit		-26.63%	-38.99%
Other Income/Expense, Net
YoY Change
Pretax Income	-$10.53M	$11.04M	$4.051M
YoY Change	-195.42%	749.15%	-9520.93%
Income Tax	$2.591M	$1.755M	$2.396M
% Of Pretax Income		15.9%	59.15%
Net Earnings	-$13.12M	$9.284M	$1.655M
YoY Change	-241.36%	381.04%	-230.31%
Net Earnings / Revenue	-9.82%	7.0%	1.43%
Basic Earnings Per Share	-$0.13	$0.09	$0.02
Diluted Earnings Per Share	-$0.13	$0.09	$0.02
COMMON SHARES
Basic Shares Outstanding	103.7M shares	101.2M shares	100.7M shares
Diluted Shares Outstanding	103.7M shares	108.6M shares	107.6M shares

Balance Sheet

Concept	2021 Q3	2020 Q3	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$933.8M	$234.5M	$346.7M
YoY Change	298.2%	-24.98%	21.82%
Cash & Equivalents	$689.8M	$234.5M	$196.8M
Short-Term Investments	$243.9M	$0.00	$149.9M
Other Short-Term Assets	$855.0K	$900.0K	$800.0K
YoY Change	-5.0%	-57.14%	-61.9%
Inventory	$22.64M	$26.48M	$26.14M
Prepaid Expenses
Receivables	$94.13M	$84.56M	$76.03M
Other Receivables	$17.60M	$37.00M	$38.10M
Total Short-Term Assets	$1.069B	$383.5M	$487.8M
YoY Change	178.76%	-5.76%	31.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.70M	$10.27M	$10.53M
YoY Change	13.9%	21.91%	25.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.74M	$11.04M	$4.860M
YoY Change	-2.75%	93.09%	-14.47%
Total Long-Term Assets	$51.45M	$47.56M	$41.16M
YoY Change	8.16%	28.84%	13.68%
TOTAL ASSETS
Total Short-Term Assets	$1.069B	$383.5M	$487.8M
Total Long-Term Assets	$51.45M	$47.56M	$41.16M
Total Assets	$1.120B	$431.0M	$528.9M
YoY Change	159.94%	-2.89%	30.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$60.01M	$42.20M	$38.50M
YoY Change	42.19%	31.88%	27.91%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$124.5M	$95.33M	$85.12M
YoY Change	30.64%	18.57%	15.71%
LONG-TERM LIABILITIES
Long-Term Debt	$561.4M	$0.00	$149.5M
YoY Change		-100.0%	0.11%
Other Long-Term Liabilities	$379.0K	$168.0K	$173.0K
YoY Change	125.6%	-43.05%	-43.46%
Total Long-Term Liabilities	$582.7M	$28.68M	$176.0M
YoY Change	1932.01%	-83.43%	1.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$124.5M	$95.33M	$85.12M
Total Long-Term Liabilities	$582.7M	$28.68M	$176.0M
Total Liabilities	$707.3M	$124.0M	$261.1M
YoY Change	470.34%	-51.08%	5.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$659.5M	-$636.0M	-$645.3M
YoY Change	3.69%	-2.92%	-1.8%
Common Stock	$0.00	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$413.2M	$307.0M	$267.8M
YoY Change
Total Liabilities & Shareholders Equity	$1.120B	$431.0M	$528.9M
YoY Change	159.94%	-2.89%	30.22%

Cashflow Statement

Concept	2021 Q3	2020 Q3	2020 Q2
OPERATING ACTIVITIES
Net Income	-$13.12M	$9.284M	$1.655M
YoY Change	-241.36%	381.04%	-230.31%
Depreciation, Depletion And Amortization	$2.734M	$2.190M	$2.600M
YoY Change	24.84%	13.47%	22.07%
Cash From Operating Activities	$24.40M	$30.97M	$12.74M
YoY Change	-21.21%	107.75%	40.54%
INVESTING ACTIVITIES
Capital Expenditures	$3.297M	$2.782M	$3.315M
YoY Change	18.51%	2.73%	38.3%
Acquisitions
YoY Change
Other Investing Activities	$306.0M	$150.0M	$0.00
YoY Change	104.0%	28201.89%	-100.0%
Cash From Investing Activities	$302.7M	$147.2M	-$3.315M
YoY Change	105.62%	-6871.76%	89.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$0.00	$1.667M
YoY Change			38.0%
Debt Paid & Issued, Net	$6.000K	$150.0M	$7.000K
YoY Change	-100.0%	2142857.14%	-12.5%
Cash From Financing Activities	$3.036M	-$140.5M	$5.345M
YoY Change	-102.16%	-1008.28%	-74.12%
NET CHANGE
Cash From Operating Activities	$24.40M	$30.97M	$12.74M
Cash From Investing Activities	$302.7M	$147.2M	-$3.315M
Cash From Financing Activities	$3.036M	-$140.5M	$5.345M
Net Change In Cash	$330.1M	$37.80M	$14.88M
YoY Change	773.39%	35.06%	-46.9%
FREE CASH FLOW
Cash From Operating Activities	$24.40M	$30.97M	$12.74M
Capital Expenditures	$3.297M	$2.782M	$3.315M
Free Cash Flow	$21.10M	$28.19M	$9.426M
YoY Change	-25.13%	131.06%	41.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001645113
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	NovoCure Limited
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	Y9
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1057807
	dei	Entity Address Address Line1 EntityAddressAddressLine1	No. 4 The Forum
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37565
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Grenville Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	St. Helier
	dei	Entity Address Country EntityAddressCountry	JE
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	JE2 4UF
	dei	City Area Code CityAreaCode	44 (0) 15
	dei	Local Phone Number LocalPhoneNumber	3475 6700
	dei	Security12b Title Security12bTitle	Ordinary Shares, no par value
	dei	Trading Symbol TradingSymbol	NVCR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	103819257	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	689837000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	234674000	USD
CY2021Q3	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	243948000	USD
CY2020Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	607902000	USD
CY2021Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	855000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	11499000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	94129000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	96699000	USD
CY2021Q3	nvcr	Receivables And Prepaid Expenses ReceivablesAndPrepaidExpenses	17595000	USD
CY2020Q4	nvcr	Receivables And Prepaid Expenses ReceivablesAndPrepaidExpenses	21245000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	22642000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	27422000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	1069006000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	999441000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11699000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11395000	USD
CY2021Q3	nvcr	Field Equipment Net Noncurrent FieldEquipmentNetNoncurrent	12553000	USD
CY2020Q4	nvcr	Field Equipment Net Noncurrent FieldEquipmentNetNoncurrent	11230000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16460000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19009000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10735000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10908000	USD
CY2021Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	51447000	USD
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	52542000	USD
CY2021Q3	us-gaap	Assets Assets	1120453000	USD
CY2020Q4	us-gaap	Assets Assets	1051983000	USD
CY2021Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	60005000	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	53647000	USD
CY2021Q3	nvcr	Other Accounts Payable Lease Liabilities And Accrued Expenses Current OtherAccountsPayableLeaseLiabilitiesAndAccruedExpensesCurrent	64544000	USD
CY2020Q4	nvcr	Other Accounts Payable Lease Liabilities And Accrued Expenses Current OtherAccountsPayableLeaseLiabilitiesAndAccruedExpensesCurrent	59965000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	124549000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	113612000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	561388000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	429905000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	7464000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	12139000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11478000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14293000	USD
CY2021Q3	nvcr	Employee Related Liabilities Non Current EmployeeRelatedLiabilitiesNonCurrent	2031000	USD
CY2020Q4	nvcr	Employee Related Liabilities Non Current EmployeeRelatedLiabilitiesNonCurrent	5171000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	379000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	337000	USD
CY2021Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	582740000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	461845000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	707289000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	575457000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	103817566	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	103817566	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	102334276	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	102334276	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1073532000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1111435000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-900000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3832000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-659468000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-631077000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	413164000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	476526000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1120453000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1051983000	USD
CY2021Q3	us-gaap	Revenues Revenues	133606000	USD
CY2020Q3	us-gaap	Revenues Revenues	132660000	USD
	us-gaap	Revenues Revenues	401818000	USD
	us-gaap	Revenues Revenues	350413000	USD
CY2020	us-gaap	Revenues Revenues	494366000	USD
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	30206000	USD
CY2020Q3	us-gaap	Cost Of Revenue CostOfRevenue	28395000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	85190000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	78365000	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	106501000	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	103400000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	104265000	USD
	us-gaap	Gross Profit GrossProfit	316628000	USD
	us-gaap	Gross Profit GrossProfit	272048000	USD
CY2020	us-gaap	Gross Profit GrossProfit	387865000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48141000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32818000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	144372000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	88008000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	132010000	USD
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	32580000	USD
CY2020Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	29364000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	98075000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	86658000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	118017000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31231000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27061000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	95116000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	79073000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	107437000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	111952000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	89243000	USD
	us-gaap	Operating Expenses OperatingExpenses	337563000	USD
	us-gaap	Operating Expenses OperatingExpenses	253739000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	357464000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8552000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	15022000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20935000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	18309000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	30401000	USD
CY2021Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	1981000	USD
CY2020Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	3983000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	5567000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	9032000	USD
CY2020	us-gaap	Interest And Debt Expense InterestAndDebtExpense	12299000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10533000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11039000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26502000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	9277000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	18102000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2591000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1755000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5391000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5614000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1706000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-13124000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	9284000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-31893000	USD
	us-gaap	Net Income Loss NetIncomeLoss	14891000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	19808000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.20
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103731147	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101234306	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103281380	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100601427	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100930866	shares
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.18
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103731147	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108643814	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103281380	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108113416	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108877648	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-13124000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	9284000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-31893000	USD
	us-gaap	Net Income Loss NetIncomeLoss	14891000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	19808000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-202000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	143000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-57000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	26000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-85000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-421000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28961000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-153000	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-2989000	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	495000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	980000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12905000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	9580000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	14422000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	18743000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	476526000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18863000	USD
CY2021Q1	nvcr	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAwardForfeitures	7961000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1884000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4128000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	372134000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27881000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2371000	USD
CY2021Q2	nvcr	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAwardForfeitures	8695000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	829000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-14641000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	397269000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25758000	USD
CY2021Q3	nvcr	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAwardForfeitures	3042000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	219000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-13124000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	413164000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	217790000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16557000	USD
CY2020Q1	nvcr	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAwardForfeitures	4511000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-862000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	3952000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	241948000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18770000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1667000	USD
CY2020Q2	nvcr	Stock Issued During Period Value Stock Options And Warrants Exercised And Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercisedAndRestrictedStockAwardForfeitures	3685000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	97000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	1655000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	267822000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20121000	USD
CY2020Q3	nvcr	Stock Issued During Period Value Stock Options And Warrants Exercised And Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercisedAndRestrictedStockAwardForfeitures	9514000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	296000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	9284000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	307037000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-13124000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	9284000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-31893000	USD
	us-gaap	Net Income Loss NetIncomeLoss	14891000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	19808000	USD
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2734000	USD
CY2020Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2188000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7584000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6677000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9150000	USD
CY2021Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	113000	USD
CY2020Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	124000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	467000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	263000	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	429000	USD
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	25758000	USD
CY2020Q3	us-gaap	Share Based Compensation ShareBasedCompensation	20121000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	72502000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	55448000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	75721000	USD
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-495000	USD
CY2020Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	79000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3024000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	549000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	699000	USD
CY2021Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3726000	USD
CY2020Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7678000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3923000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	33556000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30354000	USD
CY2021Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	785000	USD
CY2020Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	424000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2313000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-654000	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3260000	USD
CY2021Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3818000	USD
CY2020Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	55000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-4185000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2446000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2935000	USD
CY2021Q3	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1367000	USD
CY2020Q3	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	5173000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-4383000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2794000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1366000	USD
CY2021Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8126000	USD
CY2020Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9908000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10622000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	7974000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	25470000	USD
CY2021Q3	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1946000	USD
CY2020Q3	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1905000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-8758000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	413000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	664000	USD
CY2021Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	24400000	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	30969000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	68352000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	45667000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	99148000	USD
CY2021Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3297000	USD
CY2020Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2782000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9896000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9209000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14968000	USD
CY2021Q3	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	350000000	USD
CY2020Q3	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	150000000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	958000000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	150000000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	150000000	USD
CY2021Q3	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	44000000	USD
CY2020Q3	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	593848000	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	USD
CY2020	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	607879000	USD
CY2021Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	302703000	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	147218000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	354256000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	140791000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-472847000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	19000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	150022000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	150028000	USD
CY2021Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3042000	USD
CY2021Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2371000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1667000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3370000	USD
CY2021Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	558439000	USD
CY2021Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6000	USD
CY2020Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	150007000	USD
CY2020Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9514000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	19698000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17710000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	28428000	USD
CY2021Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3036000	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-140493000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22050000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-130645000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	440209000	USD
CY2021Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-34000	USD
CY2020Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-139000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	152000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	247000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	330105000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	37796000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	444519000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	55965000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	66757000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	360587000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	197585000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	246173000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179416000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179416000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	690692000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	235381000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	690692000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	235381000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	246173000	USD
CY2021Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	991000	USD
CY2020Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4382000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1075000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	11319000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-3261000	USD
CY2021Q3	us-gaap	Interest Paid Net InterestPaidNet	1000	USD
CY2020Q3	us-gaap	Interest Paid Net InterestPaidNet	1840000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3000	USD
	us-gaap	Interest Paid Net InterestPaidNet	8671000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	8686000	USD
CY2021Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1023000	USD
CY2020Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	675000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1972000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2849000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5617000	USD
CY2021Q3	us-gaap	Cash Cash	27768000	USD
CY2020Q4	us-gaap	Cash Cash	20339000	USD
CY2021Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	422082000	USD
CY2020Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	214335000	USD
CY2021Q3	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	239987000	USD
CY2020Q4	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	0	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	689837000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	234674000	USD
CY2021Q3	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	243948000	USD
CY2020Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	607902000	USD
CY2021Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	243964000	USD
CY2020Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	607905000	USD
CY2021Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1615000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5175000	USD
CY2021Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5921000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4896000	USD
CY2021Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	15106000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	17351000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	22642000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	27422000	USD
CY2021Q3	us-gaap	Deposits Assets DepositsAssets	1408000	USD
CY2020Q4	us-gaap	Deposits Assets DepositsAssets	1438000	USD
CY2021Q3	us-gaap	Contractual Obligation ContractualObligation	1747000	USD
CY2020Q4	us-gaap	Contractual Obligation ContractualObligation	1687000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9220326	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.21
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	425339	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	154.03
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	918859	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	21.54
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	101320	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	60.64
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8625486	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.61
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5153158	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.35
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	918859	shares
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25758000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20121000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72502000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55448000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75721000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-13124000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	9284000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-31893000	USD
	us-gaap	Net Income Loss NetIncomeLoss	14891000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	19808000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103731147	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101234306	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103281380	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100601427	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100930866	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103731147	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108643814	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1307762	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103281380	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108113416	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108877648	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8084045	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	952823	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8827739	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	717492	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.20
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.18
CY2021Q3	us-gaap	Noncurrent Assets NoncurrentAssets	24252000	USD
CY2020Q4	us-gaap	Noncurrent Assets NoncurrentAssets	22625000	USD
CY2021Q3	us-gaap	Revenues Revenues	133606000	USD
CY2020Q3	us-gaap	Revenues Revenues	132660000	USD
	us-gaap	Revenues Revenues	401818000	USD
	us-gaap	Revenues Revenues	350413000	USD
CY2020	us-gaap	Revenues Revenues	494366000	USD

Files In Submission

Name	View Source	Status
0001645113-21-000112-index-headers.html	Edgar Link	pending
0001645113-21-000112-index.html	Edgar Link	pending
0001645113-21-000112.txt	Edgar Link	pending
0001645113-21-000112-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvcr-20210930.htm	Edgar Link	pending
nvcr-20210930.xsd	Edgar Link	pending
nvcr-20210930xexx3111.htm	Edgar Link	pending
nvcr-20210930xexx3121.htm	Edgar Link	pending
nvcr-20210930xexx3211.htm	Edgar Link	pending
nvcr-20210930xexx3221.htm	Edgar Link	pending
nvcr-20210930_cal.xml	Edgar Link	unprocessable
nvcr-20210930_def.xml	Edgar Link	unprocessable
nvcr-20210930_g1.jpg	Edgar Link	pending
nvcr-20210930_htm.xml	Edgar Link	completed
nvcr-20210930_lab.xml	Edgar Link	unprocessable
nvcr-20210930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVCR
NovoCure Ltd Stock $nvcr

2021 Q3 Form 10-Q Financial Statement

#000164511321000112 Filed on October 28, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVCR NovoCure Ltd Stock $nvcr

2021 Q3 Form 10-Q Financial Statement

#000164511321000112 Filed on October 28, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVCR
NovoCure Ltd Stock $nvcr